---
title: "China Reform Health Management and Services Group Co.,Ltd. (000503.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000503.SZ.md"
symbol: "000503.SZ"
name: "China Reform Health Management and Services Group Co.,Ltd."
industry: "Health Care Distributors"
datetime: "2026-03-03T10:58:59.645Z"
locales:
  - [en](https://longbridge.com/en/quote/000503.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000503.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000503.SZ.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/000503.SZ.md) | [繁體中文](https://longbridge.com/zh-HK/quote/000503.SZ.md)


# China Reform Health Management and Services Group Co.,Ltd. (000503.SZ)

## Company Overview

China Reform Health Management and Services Group Co., Ltd. offers medical insurance management services in China. It provides services of medical insurance funds, medical quality and safety, drug and device supervision, and internet health protection. It is also involved in the pharmaceutical and medical business.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [www.crhms.cn](https://www.crhms.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-03T04:30:10.000Z

**Overall: D (0.70)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 23 / 25 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -11.44% |  |
| Net Profit YoY | -5273.56% |  |
| P/B Ratio | 6.89 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8756819190.46 |  |
| Revenue | 328310088.91 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -8.87% | D |
| Profit Margin | -36.03% | E |
| Gross Margin | 1.31% | E |
| Revenue YoY | -11.44% | E |
| Net Profit YoY | -5273.56% | E |
| Total Assets YoY | 8.62% | B |
| Net Assets YoY | -8.82% | D |
| Cash Flow Margin | -277.56% | D |
| OCF YoY | -11.44% | E |
| Turnover | 0.17 | D |
| Gearing Ratio | 37.02% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - China Reform Health Management and Services Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-11.44%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-5273.56%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.89",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8756819190.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "328310088.91",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-8.87%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-36.03%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "1.31%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-11.44%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-5273.56%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.62%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-8.82%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-277.56%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-11.44%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "37.02%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -74.03 | 22/25 | - | - | - |
| PB | 6.89 | 26/25 | 7.85 | 7.59 | 7.32 |
| PS (TTM) | 26.67 | 26/25 | 31.18 | 29.28 | 27.87 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | B | B |
| 02 | Jointown (600998.SH) | C | B | A | D | B | B |
| 03 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | B | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | A | D | B | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | B | C |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-23T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.42 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000503.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000503.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000503.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000503.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**